[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cervical-cancer-stage-iia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cervical-cancer-stage-iia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,53,78,113],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100612699","minimally-invasive-radical-hysterectomy-using-endoscopic-stapler-in-stage-ib2-or-iia1-cervical-cancer-100612699",false,"NCT07256977","Minimally Invasive Radical Hysterectomy Using Endoscopic Stapler in Stage IB2 or IIA1 Cervical Cancer","A Multicenter Non-inferiority Randomized Controlled Trial on Minimally Invasive Radical Hysterectomy Using an Endoscopic Stapler to Prevent Tumor Spillage in Stage IB2-IIA1 Cervical Cancer","SOLUTION2","I. Inclusion Criteria:\n\n1. 2018 FIGO stage IB2 or IIA1 cervical cancer (tumor maximum diameter ≥2 cm and \\\u003C4 cm)\n2. Histologically confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma\n3. Planned for Type B or C radical hysterectomy\n4. With adequate bone marrow, renal, and hepatic function\n\n   * WBC \\>3.0 × 10⁹ cells\u002FL\n   * Platelets \\>100 × 10⁹ cells\u002FL\n   * Creatinine \\\u003C180 μmol\u002FL\n   * Bilirubin \\\u003C1.5 × normal range\n   * AST, ALT \\\u003C 3 × normal range\n5. Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n6. Previous history of other invasive malignancies with no evidence of recurrence for at least 5 years\n7. Signed and approved consent form\n\nII. Exclusion Criteria:\n\n1. Histological types other than squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma\n2. Tumor size less than 2 cm classified as 2018 FIGO stage IA1, IA2, or IB1 disease\n3. The following are observed on preoperative CT or MRI\n\n   * Tumor size ≥4 cm\n   * Lymph node metastasis (short axis ≥15 mm)\n   * Paracervical invasion\n   * Bladder or rectal invasion\n   * Distant metastasis\n4. Prior pelvic or abdominal radiotherapy\n5. Prior neoadjuvant chemotherapy before surgery\n6. Unsuitable for surgery due to severe systemic disease at the investigator's discretion\n7. Difficult to consider intraoperative lymphatic mapping due to\n\n   * Allergy to triphenylmethane compounds\n   * History of prior retroperitoneal surgery\n   * History of prior pelvic radiotherapy\n   * Cases where cold knife or loop electrosurgical excision procedure (LEEP) was performed within 4 weeks prior to study participation\n   * Allergy to triphenylmethane compounds","FEMALE","20 Years",{"count":20,"type":21},494,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study is a multicenter, open-label, non-inferiority, randomized controlled, investigator-initiated clinical trial comparing the efficacy and safety of open radical hysterectomy versus minimally invasive radical hysterectomy using an endoscopic stapler as surgical treatments for early cervical cancer.",[27,28],"Cervical Cancer Stage IB2","Cervical Cancer Stage IIa",[30,31,32,33,34,35,36,37,38,39],"Cervical cancer","open radical hysterectomy","minimally invasive radical hysterectomy","endoscopic stapler","survival","complications","perioperative outcomes","postoperative pain","quality of life","recurrence pattern","NOT_YET_RECRUITING","2025-11-27",{"date":43,"type":44},"2025-12-02","ACTUAL",{"date":46,"type":21},"2026-01-01",{"date":48,"type":21},"2035-06-30",{"name":50,"class":51},"Seoul National University Hospital","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":52},"100612076","pilot-study-for-the-generation-of-cervical-cancer-organoids-from-patients-undergoing-diagnostic-biopsy-100612076","NCT07248878","Pilot Study for the Generation of Cervical Cancer Organoids From Patients Undergoing Diagnostic Biopsy","Cervical organ","Inclusion Criteria:\n\n* female over 18 years of age;\n* suspected diagnosis of cervical cancer for which a biopsy is indicated according to standard clinical practice;\n* Informed consent (study participation and data processing) given in writing personally and\u002For through the legal representative\u002Fguardian\u002Fsupport administrator\u002Fwitness, before any study-specific procedure is performed.\n\nExclusion Criteria:\n\n* previous malignancies;\n* previous systemic treatments;\n* previous antibiotic treatment before surgery. Any antibiotic treatment must be stopped at least 3 weeks before surgery.","18 Years",{"count":62,"type":21},24,"OBSERVATIONAL","A meta-analysis showed that neoadjuvant chemotherapy followed by radical hysterectomy reduces the risk of mortality by 35% compared to radiotherapy alone, with a 14% increase in five-year survival. Unfortunately, however, approximately 30% of patients undergoing neoadjuvant chemotherapy are referred for adjuvant radiotherapy or chemoradiotherapy due to the presence of high recurrence risk factors after surgery, which results in a bi- or tri-modal treatment with very serious consequences in terms of toxicity. Infact, approximately 20% of patients treated with radiotherapy experience vaginal discomfort up to 3 years after completing treatment, with significant consequences for the women's quality of life. Therefore, on the one hand, it would be appropriate to identify new drugs that synergize with chemotherapy, reducing the need for adjuvant radiation; on the other, it could be useful to identify patients who could truly benefit from neoadjuvant treatment. To do this, it is necessary to have ex vivo biological models capable of simulating the complexity of the tumor environment and that can be used as a tool to investigate tumor response to specific treatments.\n\nIn this context, tumor organoids represent ideal alternative in vitro models, capable of preserving the characteristics of the original tumors, including their architecture and cell types present. They can be used as avatars for the selection of specific anticancer therapies and for the creation of patient biobanks.",[27,28,66,67],"Cervical Cancer Stage IB","Cervical Cancer Stage IIIA","RECRUITING","2025-11-18",{"date":71,"type":44},"2025-11-25",{"date":73,"type":44},"2025-03-26",{"date":75,"type":21},"2028-03-26",{"name":77,"class":51},"Regina Elena Cancer Institute",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":17,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":90,"conditions":91,"keywords":98,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":112},"100467790","immune-persistence-after-the-whole-vaccination-shcedule-with-recombination-quadrivalent-hpv-vaccine-100467790","NCT05371353","Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine","Evaluating the Immune Persistence of Recombination Quadrivalent HPV Vaccine (Type 6, 11, 16, 18) in Healthy Chinese Female Subjects Aged 9 to 45 Years: A Phase 3, Open-label, Non-randomized Clinical Trial","Inclusion Criteria:\n\n* Subjects who participated in the phase III clinical trial of non inferior efficacy of HPV tetravalent vaccine of Yangchun Center for Disease Control and Prevention (protocol No.: 4-HPV-3001), completed three doses of HPV quadrivalent vaccine and provided blood sample at months 7; Or subjects who have participated in the bridging study of HPV quadrivalent vaccine of Mianyang Center for Disease Control and Prevention (scheme No.: 4-HPV-3002), completed the whole vaccine schedule at month 0，2，6, and provided blood sample at months 7;\n* The subjects aged 9 to 17 years old at Mianyang site and their legal guardian should provide legal indentification; the subjects aged over 18 years old should provide legal indentification;\n* The subject voluntarily agrees to enroll in this study. If the subject is a minor, both the subject and subject's legal guardian should voluntarily agree to enroll in this study and sign an informed consent form;\n* Be able to understand the study procedures and promise to participate in regular follow-ups under the requirements.\n\nExclusion Criteria:\n\n* Enrolling or plan to enroll in other clinical trials (drugs or vaccines) (except that the observational clinical study and the subjects at Mianyang site are still in the post exemption safety follow-up stage of the 4-HPV-3002 trial);\n* Suffering from thrombocytopenia or any coagulation dysfunction that can be a contraindication to blood collection (such as coagulation factor deficiency, coagulation diseases, platelet abnormalities, etc.);\n* According to the investigator's judgment, the subject has any condition may interfere with process of evaluation of immune persistence.",true,"9 Years","45 Years",{"count":89,"type":21},600,"To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.",[92,28,93,94,95,96,97],"HPV Infections","Vaginal Cancer","Genital Wart","CIN1","CIN2","CIN3",[99,100,101],"Human papillomavirus","vaccine","Cervical Cancer","2024-04-15",{"date":104,"type":44},"2024-04-17",{"date":106,"type":44},"2022-05-14",{"date":108,"type":21},"2027-05",{"name":110,"class":111},"Shanghai Bovax Biotechnology Co., Ltd.","INDUSTRY",2,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":85,"sex":17,"minAge":86,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":125,"conditions":126,"keywords":127,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":128,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":52},"100441393","phase-3-immunogenicity-and-safety-of-quadrivalent-hpv-vaccine-in-healthy-chinese-female-subjects-aged-9-to-19-years-100441393","NCT05027776","Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years","Evaluating the Immunogenicity and Safety of Quadrivalent Human Papillomavirus Recombinant Vaccine (Type 6, 11, 16, 18) in Healthy Chinese Female Subjects Aged 9 to 26 Years: A Phase 3, Open-label, Non-randomized Clinical Trial","Inclusion Criteria:\n\n1. Healthy Chinese females aged 9 to 26 years; Provide legal identification;\n2. The subject voluntarily agrees to enroll in this study. If the subject is a minor, both the subject and subject's legal guardian should voluntarily agree to enroll in this study and sign an informed consent form;\n3. Had a negative urine pregnancy test on the day of enrollment, among the subjects of childbearing age; Not in the duration of breast-feeding and no birth plan within 7 months; According to the investigator's judgment that there is no possibility of pregnancy at that time: subjects have taken effective contraception, or asexual life after the last menstrual period, or use IUD, or had undergone ligation; subjects agree to continue take effective contraception such as taking OCS and condom use;\n4. No fever symptoms on the day of enrollment (aged\\> 14 years old, axillary temperature\\\u003C37.3°C; aged ≤ 14 years old, axillary temperature\\\u003C37.5°C );\n5. Be able to understand the study procedures and promise to participate in regular follow-ups under the requirements;\n\nExclusion Criteria:\n\n1. Received marketed HPV vaccine or plan to receive marketed HPV vaccine during this study period or have enrolled in HPV vaccine clinical trials;\n2. Enrolling or plan to enroll in other clinical trials (drug or vaccine);\n3. History of positive test to HPV, history of cervical cancer (e.g. abnormal screening test results, abnormal cervical biopsy results, including CIN, LSIL, and cervical cancer) or history of pelvic radiotherapyherpes;\n4. History of diseases related to HPV infection (e.g. genital warts, VIN, VaIN, and related cancers) or history of STDs, including syphilis, gonorrhea, genital herpes, Mycoplasma genitalium, Lymphgranuloma Venereum, granuloma inguinale, etc.;\n5. Known allergy to any vaccine components or history of severe allergic diseases requiring treatment, including shock, laryngeal edema, urticarial, Henoch-Schonlein purpura, Arthus reaction, etc.;\n6. Had primary or acquired immunodeficiency such as HIV, SLE, JRA, etc;\n7. History of epilepsy and convulsions (except fever convulsions in children under 5 years of age);\n8. Subjects with existing infectious diseases such as TB, viral hepatitis, and\u002For HIV infection; or existing liver or kidney conditions, CVDs, and malignancy;\n9. Untreated\u002Funcontrolled hypertension before vaccination (aged 9 to 17 years: systolic BP≥120mmHg and\u002For diastolic BP≥80mmHg; aged more than 18 years: Systolic BP≥140mmHg and\u002For diastolic BP ≥90mmHg);\n10. With prohibitive contraindications such as Thrombocytopenia or coagulopathy;\n11. Asplenic, functionally asplenic, or splenectomy caused by any condition;\n12. Received immunosuppressive treatment within one month before study such as long-term glucocorticoid use(≥2mg per kg per day, lasted more than two wks), or plan to receive such treatment from month 0 to month 7；\n13. Receipt of immune globulin or blood-related products within 3 months; or plan to receive such products during this study period（month 0 to month 7）;\n14. Within 3 days prior to vaccination, have an acute disease or are in the acute attack of a chronic disease or have used antipyretic, analgesic and anti-allergic drugs (such as: acetaminophen, ibuprofen, aspirin, loratadine, ceti Rizine, etc.);\n15. Receipt of inactivated, RNA, and recombinant vaccines within 14 days, live vaccines within 28 days;\n16. Subjects with existing mental illness, History of mental illness, or Family History;\n17. According to the investigator's judgment, the subject has any condition may interfere with process of evaluation or participating in this study cannot guarantee the object's maximum benefit.","26 Years",{"count":122,"type":21},1348,[124],"PHASE3","This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years",[92,28,93,94,95,96,97],[99,100,101],{"date":104,"type":44},{"date":130,"type":44},"2021-09-15",{"date":132,"type":21},"2026-09-29",{"name":110,"class":111}]